Startup Treeline Bio Emerges From the Shadows With $1B+ Raised and 3 Cancer Drugs in the Clinic

Startup Treeline Bio Emerges From the Shadows With $1B+ Raised and 3 Cancer Drugs in the Clinic

Eschewing the traditional model of financing biotech startups milestone to milestone to support a lead asset, Treeline Biosciences’ well-funded pipeline is comprised of multiple complementary programs. Select investors have supported the approach of Treeline, which said it has raised more than $1.1 billion to date. The post Startup Treeline Bio Emerges From the Shadows With $1B+ Raised and 3 Cancer Drugs in the Clinic appeared first on MedCity N…

Secretive startup Treeline unveils first clinical candidates, $200M in new funding

The biotech started by Loxo founder Josh Bilenker and former Novartis executive Jeff Engelman has advanced three cancer drugs to Phase 1 trials.

Josh Bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B

After four and a half years of staying relatively quiet on its pipeline and exact financing details, Treeline Biosciences is finally coming out with some specifics on its drug candidates as a couple